Eli Lilly (LLY) Responds to FDA Adverse Report on Foundayo

 Wolfe Research reported a serious case of liver failure associated with Eli Lilly’s LLY drug, Foundayo, which raised concerns regarding the drug's safety. In response, Eli Lilly stated that their Global Patient Safety team reviewed the report and concluded that the event was unlikely to be connected to Foundayo. Analysts believe the market's reaction during pre-market trading was exaggerated, viewing this as a buying opportunity and maintaining an optimistic stance on the stock with a price target of $1,325.

The recent report of liver failure linked to Eli Lilly's Foundayo drug has raised significant concerns among investors and analysts. The FDA's Adverse Event Reporting System flagged this serious case, prompting analysts to seek clarification from the company. Eli Lilly's prompt response, stating that their review found no likely connection between the drug and the adverse event, aims to reassure stakeholders and mitigate fears surrounding the drug's safety profile.

https://www.gurufocus.com/news/8839796/eli-lilly-lly-responds-to-fda-adverse-report-on-foundayo